Dual antiplatelet therapy as a long-term action in secondary prevention after myocardial infarction: focus on ticagrelor

Cover Page

Cite item

Full Text

Abstract

The analytical article realized the current status of antiplatelet prevention in patients with history of myocardial infarction. After brief historical information the design and results of the PEGASUS-TIMI 54 study (Prevention of Cardiovascular Events in Patients with a Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) particularly discussed. The results of the study showed that P2Y12 platelet receptor inhibitor ticagrelor can be considered as basic element of long-term dual antiplatelet therapy in patients after myocardial infarction. The final decision concerning the possibility of ticagrelor application in a new indication should be given by the special allowing organizations and expert communities. The study results let us suppose that ticagrelor 60 mg twice daily can be used for discussed purpose in clinical practice in future.

About the authors

O. V Averkov

People’s Friendship University of Russia; O.M.Filatov City clinical hospital №15 of the Department of Health of Moscow

Email: oleg.averkov@gmail.com
д-р мед. наук, проф. каф. терапии фак-та повышения квалификации мед. работников ФГАОУ ВО РУДН, зам. глав. врача, рук. регионального сосудистого центра ГБУЗ ГКБ №15 им. О.М.Филатова 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6

References

  1. Sabatine M.S, Cannon C.P, Gibson C.M et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
  2. Chen Z.M, Jiang L.X, Chen Y.P et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo - controlled trial. Lancet 2005; 366: 1607-21.
  3. Wiviott S.D, Braunwald E, Mc Cabe C.H et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
  4. Wallentin L, Becker R.C, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. doi: 10.1056/NEJMoa0904327.
  5. Steg G, James D.K, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569-619.
  6. O’Gara P.T, Kushner F.G, Ascheim D.D et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012, 10.1161/CIR.0b013e3182742c84.
  7. Hamm C.W, Bassand J.P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
  8. Amsterdam E.A, Wenger N.K, Brindis R.G et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130 (25): 2354-94.
  9. Fox K.A, Anderson F.A.Jr, Goodman S.G et al. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nat Clin Pract Cardiovasc Med 2008; 5 (9): 580-9.
  10. Rapsomaniki E, Thuresson M, Yang E et al. International comparison of outcomes among 140880 patients stable after acute MI; real world evidence from electronic health and administrative records. Presented at European Society of Cardiology Congress, Barcelona, Spain; 30 August - 3 September 2014.
  11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case - control study. BMJ 2006; 333: 726-30.
  12. Delaney J.A, Opatrny L, Brophy J.M, Suissa S. Drug - drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177: 347-51.
  13. Bonaca M.P, Bhatt D.L, Cohen M et al. Long - term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; Doi: 10156/NEJMoa1500857.
  14. Bhatt D.L, Fox K.A, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006; 354: 1706-17.
  15. Bhatt D.L, Flather M.D, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-8.
  16. Morrow D.A, Braunwald E, Bonaca M.P et al. TRA 2P-TIMI 50 Steering Committee and, Investigators (Apr 12, 2012). Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404-13.
  17. Scirica B.M, Bonaca M.P, Braunwald E et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P-TIMI 50 trial. Lancet 2012; 380: 1317-24

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies